Oncotelic Therapeutics Inc. OTLC Archives

MondayJun 08, 2026 9:20 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Showcase AI Drug Discovery Platform at Qdrant Vector Space Day 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced that its proprietary PDAOAI(TM) drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development. The presentation will highlight several innovations underpinning the platform, including a proprietary "manifold folding" technique designed to improve semantic…

FridayJun 05, 2026 10:30 am

Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation

OTLC continues to advance its Deciparticle nanomedicine platform, with expanding international development initiatives supporting future therapeutic and commercial opportunities. The company's PDAOAI ecosystem now incorporates 28 million scientific abstracts and is being deployed into real-world pharmaceutical automation applications through TechForce Robotics. The company is leveraging AI, nanomedicine, and automation to accelerate therapies for cancer and rare diseases. Oncotelic Therapeutics (OTCQB: OTLC) is strategically placing itself at the nexus of precision oncology, advanced automation, and artificial intelligence. Through its PDAOAI artificial intelligence ecosystem, Deciparticle(TM) nanomedicine platform, and emerging robotics initiatives, the company is quickly building an integrated technology portfolio built to…

ThursdayJun 04, 2026 10:15 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Drug-Delivery Market Growth

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in a BioMedWire editorial examining growing investor interest in platform biotech companies as the global drug-delivery market advances toward an estimated $410 billion opportunity. The editorial highlights increasing industry focus on overcoming challenges related to drug penetration, tumor targeting, therapeutic resistance and maintaining consistent intratumoral exposure, while spotlighting Oncotelic’s Sapu003 and Deciparticle platform as examples of nanotechnology-driven drug-delivery approaches designed to enhance the clinical utility of existing therapies through improved pharmacokinetics and delivery performance. To view the full press release, visit https://ibn.fm/laaQ6 About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical…

WednesdayJun 03, 2026 9:50 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial exploring how biotechnology companies are increasingly leveraging advanced drug-delivery technologies, nanotechnology platforms and artificial intelligence to enhance existing therapies and expand treatment opportunities. The article highlights Oncotelic’s Sapu003 program, Deciparticle(TM) platform and PDAOAI initiative as part of a broader industry trend toward scalable, multi-application biotechnology platforms capable of supporting oncology and rare disease programs. The editorial also discusses developments from CytoDyn Inc. (OTCQB: CYDY), which is advancing leronlimab for oncology indications; Revolution Medicines Inc. (NASDAQ: RVMD), which reported positive Phase 3 results for daraxonrasib in pancreatic cancer; Moderna Inc. (NASDAQ:…

MondayJun 01, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Holds $388M JV Valuation as Pipeline Momentum Builds

Oncotelic Therapeutics maintained the fair value of its 45% GMP Biotechnology JV stake at approximately $388 million in Q1 2026 despite broader biotech market volatility The valuation was supported by an independent ASC 820 Level 3 assessment using discounted cash flow analysis and market comparables These developments reinforce Oncotelic’s partnership-driven model, designed to advance a multi-billion-dollar oncology pipeline while limiting traditional biotech cash burn pressures Oncotelic Therapeutics (OTCQB: OTLC) continues to distinguish itself within a biotechnology sector often characterized by aggressive capital raises and persistent cash burn. In its recently filed first-quarter 2026 financial results, the company maintained the fair…

TuesdayMay 26, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Advances CNS Drug Delivery Strategy as BBB Breakthroughs Drive New Biotech Market Opportunity

OTLC completed a $12.5M monetization of its N2B CNS delivery system with Lunai Bioworks, targeting Alzheimer’s and biodefense applications The deal grants field-specific IP rights while preserving Oncotelic’s development in other CNS indications The move aligns with the rising industry focus on blood-brain barrier (“BBB”) bypass technologies and platform-based CNS drug delivery Oncotelic Therapeutics (OTCQB: OTLC) is advancing its position in one of biotechnology’s most persistent and commercially significant challenges: drug delivery to the central nervous system (“CNS”). As the industry increasingly recognizes the blood-brain barrier (“BBB”) as a primary constraint in neurological drug development, companies developing delivery-focused platforms are…

ThursdayMay 21, 2026 11:15 am

Oncotelic Therapeutics Inc. (OTLC) Proving Small Biotech Can Out-Innovate Big Pharma with 28 Million Reasons Why

The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and is projected to reach more than $10 billion by 2031. Oncotelic's central technology, the PDAOAI platform, was designed from the outset to be something more than a research accelerator for internal programs. The most significant development to date came when Oncotelic announced the successful integration of approximately 28 million scientific abstracts, into its PDAOAI platform. Artificial intelligence is no longer a buzzword in the life sciences; rather, it is rapidly becoming the defining infrastructure layer of modern drug development. The companies that control the most intelligent platforms…

TuesdayMay 19, 2026 1:54 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech with AI-Enhanced Robotics Strategy

Oncotelic Therapeutics (OTCQB: OTLC) is moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. “Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments,” reads a recent article. “At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise, the companies aim to deliver a GMP-compliant robotics solution capable…

WednesdayMay 13, 2026 9:20 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Next-Generation CNS Drug Delivery

Oncotelic Therapeutics (OTCQB: OTLC) was featured in BioMedWire editorial coverage examining the growing urgency around effective central nervous system drug delivery, with the company highlighted for its proprietary intranasal nose-to-brain delivery platform designed to bypass the blood-brain barrier and deliver therapeutics directly to the brain. The editorial points to rising global Alzheimer’s cases and increased biodefense focus as major catalysts driving demand for faster, more targeted CNS delivery technologies, positioning Oncotelic’s platform-based approach as part of a broader shift toward delivery innovation as a critical determinant of therapeutic success. The coverage also places Oncotelic alongside major biopharma and advanced therapeutics…

TuesdayMay 12, 2026 9:10 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS Drug Delivery Innovation

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in a BioMedWire editorial examining emerging breakthroughs in central nervous system drug delivery and the growing market opportunities tied to overcoming the blood-brain barrier. The editorial highlights Oncotelic’s proprietary intranasal nose-to-brain delivery platform, which is designed to enable rapid, targeted therapeutic access to the brain, positioning the company within a broader industry effort to advance next-generation treatments for neurological disease, biodefense applications and other CNS-related conditions. To view the full press release, visit https://ibn.fm/Y8E3U About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy…

Site Search

Company Search

Tag: Oncotelic Therapeutics Inc. OTLC